Zydus undertakes not to commercially manufacture or launch Dabrafenib until Novartis’ Indian patent expires in May 2029; statutory Bolar rights remain protected
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.